# Aktis Oncology

> Clinical-stage radiopharmaceutical company targeting solid tumors with alpha emitters.

## Why it is interesting

Aktis builds miniprotein radioconjugates for cancers underserved by existing radiopharma — incubated at MPM and IPO'd on Nasdaq (AKTS) in Jan 2026.

## Profile

- **Stage:** public
- **Status:** public
- **Industries:** biotech, healthcare
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- IPO (Jan 2026): upsized offering on Nasdaq (AKTS); ~$318M gross proceeds (Aktis investor relations)
- Series B (Sep 2024): $175M led by RA Capital; RTW, Janus Henderson participated (PR Newswire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
- Source: https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-announces-pricing-its-upsized-initial-public

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/aktis-oncology